Anifrolumab shows long-term promise in patients with lupus Researchers report positive results from the first placebo-controlled long-term trial of anifrolumab—a human monoclonal antibody that targets the type I IFN receptor—in patients with lupus. https://t.co/IlgEUKkMOv https://t.co/kpSt61d5Qx